Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity

Metabolism: Clinical and Experimental

Volumn 45, Issue 3, 1996, Pages 342-346

  Maccario, Mauro ^a   Procopio, Massimo ^a   Grottoli, Silvia ^a   Oleandri, Salvatore Endrio ^a   Boffano, Gian Mario ^a   Taliano, Marina ^a   Camanni, Franco ^a   Ghigo, Ezio ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ARGININE; ATENOLOL; FATTY ACID; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PYRIDOSTIGMINE; SERMORELIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029930916     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90288-7     Document Type: Article

References (39)

1. Glass AR, Burman KD, Daahms WT, et al: Endocrine function in human obesity. Metabolism 30:89-104, 1981
2. Veldhuis JD, Iranmanesh A, Ho KKY, et al: Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 72:51-59, 1991
3. Williams T, Berelowitz M, Joffe SN, et al: Impaired growth hormone responses to growth hormone-releasing factor in obesity. N Engl J Med 311:1403-1407, 1984
4. Bell JP, Donald RA, Espiner EA: Pituitary response to insulin-induced hypoglycemia in obese subjects before and after fasting. J Clin Endocrinol Invest 31:546-550, 1970
5. Copinschi G, Wegienka LC, Hane S, et al: Effect of arginine on serum levels of insulin and growth hormone in obese subjects. Metabolism 16:485-491, 1967
6. Berelowitz M, Finkelstein JA, Thominet JL, et al: Impaired growth hormone secretion in spontaneous experimental obesity: A result of increased somatostatin (SRIF) tone. 64th Annual Meeting of the Endocrine Society, San Antonio, TX, 1983, p 84 (abstr 16)
7. Tannenbaum GS, Lapointe M, Gurd W, et al: Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: Roles of growth hormone-releasing factor and somatostatin. Endocrinology 127:3087-3095, 1990
8. Frohman LA, Downs TR, Sato M: Use of transgenic and genetic models to study the neuroendocrine regulation of growth hormone secretion, in Muller EE, Cocchi D, Locatelli V (eds): Growth Hormone and Somatomedins During Lifespan. Berlin, Germany, Springer Verlag, 1993, pp 131-140
9. Cordido F, Casanueva FF, Dieguez C: Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: Evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. J Clin Endocrinol Metab 68:290-293, 1989
10. Loche S, Pintus S, Carta D, et al: The effect of atenolol on the growth hormone response to growth hormone-releasing hormone in obese children. Acta Endocrinol (Copenh) 126:124-127, 1992
11. Ghigo E, Procopio M, Boffano GM, et al: Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism 41:560-563, 1992
12. Ghigo E, Procopio M, Maccario M, et al: Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity? Horm Metab Res 25:305-308, 1993
13. Cordido F, Penalva A, Dieguez C, et al: Massive growth hormone (GH) discharge in obese subjects after combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 76:819-823, 1993
14. Bowers CY: Novel GH-releasing peptides, in Melmed S (ed): Proceedings of the Third International Pituitary Congress. Los Angeles, CA, UCLA, 1994, pp 153-157
15. Tanaka K, Inoue S, Numata K, et al: Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-Dopa in obesity. Metabolism 39:892-896, 1990
16. Melmed S: Insulin suppresses growth hormone secretion by rat pituitary cells. J Clin Invest 73:1425-1433, 1984
17. Press M, Caprio S, Tamborlane WV, et al: Pituitary response to growth hormone-releasing hormone in IDDM. Abnormal response to insulin and hyperglycemia. Diabetes 41:17-21, 1992
18. Opie LH, Walfish P: Plasma free fatty acid concentration in obesity. N Engl J Med 186:757-760, 1963
19. Golay A, Swislocki ALM, Chen Y-DY, et al: Effect of obesity on ambient plasma glucose, free fatty acids, insulin, growth hormone, and glucagon concentration. J Clin Endocrinol Metab 63:481-484, 1986
20. Blackard WG, Hull EW, Lopez A: Effects of lipids on growth hormone secretion in humans. J Clin Invest 50:1439-1443, 1971
21. Imaki T, Shibasaki T, Shizume K, et al: The effect of free fatty acids on growth hormone (GH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol Metab 60:290-293, 1985
22. Fuccella L, Goldaniga G, Lovisolo P, et al: Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 28:790-795, 1980
23. Alba-Roth J, Albrecht Muller O, Schopohl J, et al: Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab 67:1186-1189, 1988
24. Leidy JW, Romano TM, Miliard WJ: Developmental and sex-related changes of the growth hormone axis in lean and obese Zucker rats. Neuroendocrinology 57:213-223,1993
25. Pontiroli AE, Lanzi R, Monti LD, et al: Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects. J Endocrinol Invest 13:539-542, 1990
26. Mazza E, Ghigo E, Goffi S, et al: Effect of potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone. J Endocrinol Invest 12:795-798, 1989
27. Andreotti AC, Lanzi R, Manzoni MF, et al: Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects. Metabolism 43:1207-1213, 1994
28. Quabbe HJ, Bumke-Vogt C, Iglesias-Rozas JR, et al: Hypothalamic modulation of growth hormone secretion in the rhesus monkey: Evidence from intracerebro-ventricular infusions of glucose, free fatty acids and ketone bodies. J Clin Endocrinol Metab 73:765-770, 1991
29. Taylor LM, Blackard WG: Effects of lipids on growth hormone synthesis by isolated pituitaries. Proc Soc Exp Biol Med 137:1026-1028, 1971
30. Renier G, Abribat T, Brazeau P, et al: Cellular mechanism of caprylic acid-induced growth hormone suppression. Metabolism 39:1108-1112, 1990
31. Alvarez CV, Mallo F, Burguera B, et al: Evidence for a direct pituitary inhibition by free fatty acids of in vivo growth hormone responses to growth hormone-releasing hormone in the rat. Neuroendocrinology 53:185-189, 1991
32. Penalva A, Gaztambide S, Vazquez JA, et al: Role of cholinergic muscarinic pathways on the free fatty acid inhibition of GH responses to GHRH in normal man. Clin Endocrinol (Oxf) 33:171-176, 1990
33. Maccario M, Procopio M, Loche S, et al: Interaction of free fatty acids and arginine on growth hormone secretion in man. Metabolism 43:223-226, 1994
34. Casabiel X, Pandiella A, Casanueva FF: Cis-unsaturated free fatty acids (FFA) block signal transduction at membrane level. J Endocrinol Invest 12:160, 1989 (suppl 2, abstr)
35. Ghigo E, Arvat E, Goffi S, et al: Repetitive GHRH and arginine administration to explore the maximal secretory capacity of somatotroph cells during lifespan. Exp Clin Endocrinol 10:191-198, 1991
36. Senaris RM, Lewis MD, Lago F, et al: Effect of free fatty acids on somatostatin secretion, content and mRNA levels in cortical and hypothalamic fetal rat neurons in monolayer culture. J Mol Endocrinol 10:207-214, 1993
37. Polosky KS, Given BD, Van Cauter E: 24-Hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 82:442-448, 1988
38. Karam JH, Grodsky GM, Forsham PH: Excessive insulin response to glucose in obese subjects measured by immunochemical assay. Diabetes 12:197-201, 1963
39. Worm D, Henriksen JE, Vaag A, et al: Pronounced blood glucose lowering effect of the antilipolytic drug acipimox in non-insulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 78:717-721, 1994